Allogene Therapeutics said its off-the-shelf CAR-T, cema-cel, achieved an interim goal in an ongoing phase 3 trial in B-cell lymphoma. In the interim analysis, 58% of treated patients reached minimal residual disease (MRD) negativity versus 16% in an observational control arm. The company framed the MRD improvement as a step toward reducing relapse risk at the end of first-line treatment in high-risk patients, while emphasizing the interim nature of the data. Earlier trial milestones and trial design details will likely influence how quickly the program progresses and how endpoints are operationalized. The update keeps momentum for “ready-to-dose” CAR-T approaches aimed at reducing treatment delays and access barriers.